Peter G. Pappas
Member of Clinical Advisory BoardDr. Peter G. Pappas, M.D., FACP, served as an Advisor of T2 Biosystems, Inc. Dr. Pappas serves as Member of Scientific Advisory Board of Matinas BioPharma Holdings, Inc and SCYNEXIS, Inc. Dr. Pappas has been a Member of Clinical Advisory Board at T2 Biosystems, Inc. since May 2011. Dr. Pappas is a Professor of Medicine in the Division of Infectious Diseases, Department of Medicine at the University of Alabama in Birmingham. Dr. Pappas was on the clinical faculty at the University of North Carolina School of Medicine in Chapel Hill, NC, through its affiliated hospital in Wilmington, North Carolina. In 1988, he joined the faculty at the University of Alabama in Birmingham School of Medicine, with a focus on infections in immunocompromised hosts, with a specific focus on the invasive mycoses. He has led numerous clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis and histoplasmosis through his involvement with the National Institute of Allergy and Infectious Disease (NIAID) Bacteriology and Mycology Study Group (BAMSG) and the MSGERC. His main areas of research interest have included the development of new therapies for fungal infections and understanding the epidemiology of candidiasis, the endemic mycoses and cryptococcosis. He has led a number of randomized clinical trials in candidiasis, cryptococcosis, aspergillosis, sporotrichosis, blastomycosis and histoplasmosis. He is the Principal Investigator for the MSG, a clinical trials group that performs international multicenter trials, creates treatment guidelines for invasive mycoses, describes the evolving epidemiology of fungal infections and explores newer diagnostic modalities for the more common mycoses. He is also PI of the Organ Transplant Infection Detection and Prevention Program (OTIP), a collaborative multicenter group funded by CDC to explore the risk factors and epidemiology of transplant associated infections. Dr. Pappas was the principal investigator of a national network of transplant centers, TRANSNET, a collaborative effort of the Centers for Disease Control and Prevention (CDC) and a consortium of industry co-sponsors to provide important epidemiologic and treatment information to transplant recipients who develop proven and probable invasive fungal infections. Dr. Pappas has published more than 130 peer-reviewed manuscripts, over 50 chapters, over 130 abstracts for scientific meetings and has co-authored 6 books. Dr. Pappas earned his medical degree in 1978 from the University of Alabama School of Medicine in Birmingham. He completed his residency in internal medicine, chief medical residency and infectious diseases fellowship at the University of Washington in Seattle.
Positions
- Company NameT2 Biosystems, Inc.Stock CodeTTOOPositionMember of Clinical Advisory BoardColleagues
- CRCraig R. JalbertCEO, President, Corporate Treasurer, Corporate Secretary & Director
- KJKelley J. MorganChief People Officer
- BABrett A. GiffinChief Commercial Officer
- RSRoger SmithSenior Vice President of Science Research & Development
- ESEric S. RosenbergMember of Clinical Advisory Board
- LBLouis B. RiceMember of Clinical Advisory Board
- MAMichael A. PfallerMember of Clinical Advisory Board
